JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Jazz Pharmaceuticals PLC

Closed

SectorHealthcare

138.49 0.39

Overview

Share price change

24h

Current

Min

138.1

Max

139.22

Key metrics

By Trading Economics

Income

-626M

-718M

Sales

148M

1B

P/E

Sector Avg

15.775

37.461

Profit margin

-68.706

Employees

2,800

EBITDA

-623M

-514M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.04% upside

Dividends

By Dow Jones

Next Earnings

5 Nov 2025

Market Stats

By TradingEconomics

Market Cap

1.2B

8.3B

Previous open

138.1

Previous close

138.49

News Sentiment

By Acuity

29%

71%

62 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Jazz Pharmaceuticals PLC Chart

Past performance is not a reliable indicator of future results.

Related News

21 Nov 2024, 14:45 UTC

Major Market Movers

Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK

31 Oct 2024, 15:29 UTC

Major Market Movers

Avadel Pharma Shares Rise on Favorable Ruling for FDA in Lumryz Litigation

Peer Comparison

Price change

Jazz Pharmaceuticals PLC Forecast

Price Target

By TipRanks

40.04% upside

12 Months Forecast

Average 194 USD  40.04%

High 230 USD

Low 147 USD

Based on 13 Wall Street analysts offering 12 month price targets forJazz Pharmaceuticals PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 111.22Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

62 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat